scholarly journals RNA Phage VLP-Based Vaccine Platforms

2021 ◽  
Vol 14 (8) ◽  
pp. 764
Author(s):  
David S. Peabody ◽  
Julianne Peabody ◽  
Steven B. Bradfute ◽  
Bryce Chackerian

Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format. Here we update the current state of development of RNA phage VLPs as platforms for presentation of diverse antigens by genetic, enzymatic, and chemical display methods.

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181182 ◽  
Author(s):  
Dandan Zhao ◽  
Bo Sun ◽  
Shiyang Sun ◽  
Bin Fu ◽  
Chuntian Liu ◽  
...  

2019 ◽  
Author(s):  
Jo-Anne Chan ◽  
David Wetzel ◽  
Linda Reiling ◽  
Kazutoyo Miura ◽  
Damien Drew ◽  
...  

ABSTRACTThe development of effective malaria vaccines remains a global health priority. Currently, the most advanced vaccine, known as RTS,S, has only shown modest efficacy in clinical trials. Thus, the development of more efficacious vaccines by improving the formulation of RTS,S for increased efficacy or to interrupt malaria transmission are urgently needed. The RTS,S vaccine is based on the presentation of a fragment of the sporozoite antigen on the surface of virus-like particles (VLPs) based on human hepatitis B virus (HBV). In this study, we have developed and evaluated a novel VLP platform based on duck HBV (known as Metavax) for malaria vaccine development. This platform can incorporate large and complex proteins into VLPs and is produced in a Hansenula cell line compatible with cGMP vaccine production. Here, we have established the expression of leading P. falciparum malaria vaccine candidates as VLPs. This includes Pfs230 and Pfs25, which are candidate transmission-blocking vaccine antigens. We demonstrated that the VLPs effectively induce antibodies to malaria vaccine candidates with minimal induction of antibodies to the duck-HBV scaffold antigen. Antibodies to Pfs230 also recognised native protein on the surface of gametocytes, and antibodies to both Pfs230 and Pfs25 demonstrated transmission-reducing activity in standard membrane feeding assays. These results establish the potential utility of this VLP platform for malaria vaccines, which may be suitable for the development of multi-component vaccines that achieve high vaccine efficacy and transmission-blocking immunity.


2010 ◽  
Vol 6 (5) ◽  
pp. 407-419 ◽  
Author(s):  
Michel Deschuyteneer ◽  
Abdelatif Elouahabi ◽  
Dominique Plainchamp ◽  
Michel Plisnier ◽  
Dominique Soete ◽  
...  

2008 ◽  
Vol 380 (1) ◽  
pp. 252-263 ◽  
Author(s):  
David S. Peabody ◽  
Brett Manifold-Wheeler ◽  
Alexander Medford ◽  
Sheldon K. Jordan ◽  
Jerri do Carmo Caldeira ◽  
...  

FEBS Letters ◽  
2000 ◽  
Vol 482 (3) ◽  
pp. 261-264 ◽  
Author(s):  
Indulis Cielens ◽  
Velta Ose ◽  
Ivars Petrovskis ◽  
Anna Strelnikova ◽  
Regina Renhofa ◽  
...  

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 981
Author(s):  
Alexander K. Andrianov ◽  
Thomas R. Fuerst

Development of preventive vaccines against hepatitis C virus (HCV) remains one of the main strategies in achieving global elimination of the disease. The effort is focused on the quest for vaccines capable of inducing protective cross-neutralizing humoral and cellular immune responses, which in turn dictate the need for rationally designed cross-genotype vaccine antigens and potent immunoadjuvants systems. This review provides an assessment of the current state of knowledge on immunopotentiating compounds and vaccine delivery systems capable of enhancing HCV antigen-specific immune responses, while focusing on the synergy and interplay of two modalities. Structural, physico-chemical, and biophysical features of these systems are discussed in conjunction with the analysis of their in vivo performance. Extreme genetic diversity of HCV-a well-known hurdle in the development of an HCV vaccine, may also present a challenge in a search for an effective immunoadjuvant, as the effort necessitates systematic and comparative screening of rationally designed antigenic constructs. The progress may be accelerated if the preference is given to well-defined molecular immunoadjuvants with greater formulation flexibility and adaptability, including those capable of spontaneous self-assembly behavior, while maintaining their robust immunopotentiating and delivery capabilities.


Author(s):  
G.D. Danilatos

Over recent years a new type of electron microscope - the environmental scanning electron microscope (ESEM) - has been developed for the examination of specimen surfaces in the presence of gases. A detailed series of reports on the system has appeared elsewhere. A review summary of the current state and potential of the system is presented here.The gas composition, temperature and pressure can be varied in the specimen chamber of the ESEM. With air, the pressure can be up to one atmosphere (about 1000 mbar). Environments with fully saturated water vapor only at room temperature (20-30 mbar) can be easily maintained whilst liquid water or other solutions, together with uncoated specimens, can be imaged routinely during various applications.


Sign in / Sign up

Export Citation Format

Share Document